These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 38458890)

  • 21. Gene and pathway level analyses of germline DNA-repair gene variants and prostate cancer susceptibility using the iCOGS-genotyping array.
    Saunders EJ; Dadaev T; Leongamornlert DA; Al Olama AA; Benlloch S; Giles GG; Wiklund F; Gronberg H; Haiman CA; Schleutker J; Nordestgaard BG; Travis RC; Neal D; Pasayan N; Khaw KT; Stanford JL; Blot WJ; Thibodeau SN; Maier C; Kibel AS; Cybulski C; Cannon-Albright L; Brenner H; Park JY; Kaneva R; Batra J; Teixeira MR; Pandha H; Govindasami K; Muir K; ; ; ; Easton DF; Eeles RA; Kote-Jarai Z
    Br J Cancer; 2016 Apr; 114(8):945-52. PubMed ID: 26964030
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A prospective prostate cancer screening programme for men with pathogenic variants in mismatch repair genes (IMPACT): initial results from an international prospective study.
    Bancroft EK; Page EC; Brook MN; Thomas S; Taylor N; Pope J; McHugh J; Jones AB; Karlsson Q; Merson S; Ong KR; Hoffman J; Huber C; Maehle L; Grindedal EM; Stormorken A; Evans DG; Rothwell J; Lalloo F; Brady AF; Bartlett M; Snape K; Hanson H; James P; McKinley J; Mascarenhas L; Syngal S; Ukaegbu C; Side L; Thomas T; Barwell J; Teixeira MR; Izatt L; Suri M; Macrae FA; Poplawski N; Chen-Shtoyerman R; Ahmed M; Musgrave H; Nicolai N; Greenhalgh L; Brewer C; Pachter N; Spigelman AD; Azzabi A; Helfand BT; Halliday D; Buys S; Ramon Y Cajal T; Donaldson A; Cooney KA; Harris M; McGrath J; Davidson R; Taylor A; Cooke P; Myhill K; Hogben M; Aaronson NK; Ardern-Jones A; Bangma CH; Castro E; Dearnaley D; Dias A; Dudderidge T; Eccles DM; Green K; Eyfjord J; Falconer A; Foster CS; Gronberg H; Hamdy FC; Johannsson O; Khoo V; Lilja H; Lindeman GJ; Lubinski J; Axcrona K; Mikropoulos C; Mitra AV; Moynihan C; Ni Raghallaigh H; Rennert G; Collier R; ; Offman J; Kote-Jarai Z; Eeles RA
    Lancet Oncol; 2021 Nov; 22(11):1618-1631. PubMed ID: 34678156
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inherited DNA Repair Gene Mutations in Men with Lethal Prostate Cancer.
    Rantapero T; Wahlfors T; Kähler A; Hultman C; Lindberg J; Tammela TL; Nykter M; Schleutker J; Wiklund F
    Genes (Basel); 2020 Mar; 11(3):. PubMed ID: 32183364
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comprehensive Clinical and Genetic Analysis of
    Kirchner K; Gamulin M; Kulis T; Sievers B; Kastelan Z; Lessel D
    Genes (Basel); 2022 Oct; 13(11):. PubMed ID: 36360192
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Identification of germline MLH1 alterations in familial prostate cancer.
    Fredriksson H; Ikonen T; Autio V; Matikainen MP; Helin HJ; Tammela TL; Koivisto PA; Schleutker J
    Eur J Cancer; 2006 Nov; 42(16):2802-6. PubMed ID: 16963262
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Patient-derived xenografts reveal that intraductal carcinoma of the prostate is a prominent pathology in BRCA2 mutation carriers with prostate cancer and correlates with poor prognosis.
    Risbridger GP; Taylor RA; Clouston D; Sliwinski A; Thorne H; Hunter S; Li J; Mitchell G; Murphy D; Frydenberg M; Pook D; Pedersen J; Toivanen R; Wang H; Papargiris M; Lawrence MG; Bolton DM
    Eur Urol; 2015 Mar; 67(3):496-503. PubMed ID: 25154392
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hereditary Predisposition to Prostate Cancer: From Genetics to Clinical Implications.
    Brandão A; Paulo P; Teixeira MR
    Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32708810
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rare Germline Variants Are Associated with Rapid Biochemical Recurrence After Radical Prostate Cancer Treatment: A Pan Prostate Cancer Group Study.
    Burns D; Anokian E; Saunders EJ; Bristow RG; Fraser M; Reimand J; Schlomm T; Sauter G; Brors B; Korbel J; Weischenfeldt J; Waszak SM; Corcoran NM; Jung CH; Pope BJ; Hovens CM; Cancel-Tassin G; Cussenot O; Loda M; Sander C; Hayes VM; Dalsgaard Sorensen K; Lu YJ; Hamdy FC; Foster CS; Gnanapragasam V; Butler A; Lynch AG; Massie CE; ; Woodcock DJ; Cooper CS; Wedge DC; Brewer DS; Kote-Jarai Z; Eeles RA
    Eur Urol; 2022 Aug; 82(2):201-211. PubMed ID: 35659150
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prostate Cancer Risks for Male BRCA1 and BRCA2 Mutation Carriers: A Prospective Cohort Study.
    Nyberg T; Frost D; Barrowdale D; Evans DG; Bancroft E; Adlard J; Ahmed M; Barwell J; Brady AF; Brewer C; Cook J; Davidson R; Donaldson A; Eason J; Gregory H; Henderson A; Izatt L; Kennedy MJ; Miller C; Morrison PJ; Murray A; Ong KR; Porteous M; Pottinger C; Rogers MT; Side L; Snape K; Walker L; Tischkowitz M; Eeles R; Easton DF; Antoniou AC
    Eur Urol; 2020 Jan; 77(1):24-35. PubMed ID: 31495749
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Germline Mutations in ATM and BRCA1/2 Distinguish Risk for Lethal and Indolent Prostate Cancer and are Associated with Early Age at Death.
    Na R; Zheng SL; Han M; Yu H; Jiang D; Shah S; Ewing CM; Zhang L; Novakovic K; Petkewicz J; Gulukota K; Helseth DL; Quinn M; Humphries E; Wiley KE; Isaacs SD; Wu Y; Liu X; Zhang N; Wang CH; Khandekar J; Hulick PJ; Shevrin DH; Cooney KA; Shen Z; Partin AW; Carter HB; Carducci MA; Eisenberger MA; Denmeade SR; McGuire M; Walsh PC; Helfand BT; Brendler CB; Ding Q; Xu J; Isaacs WB
    Eur Urol; 2017 May; 71(5):740-747. PubMed ID: 27989354
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Germline BRCA mutations denote a clinicopathologic subset of prostate cancer.
    Gallagher DJ; Gaudet MM; Pal P; Kirchhoff T; Balistreri L; Vora K; Bhatia J; Stadler Z; Fine SW; Reuter V; Zelefsky M; Morris MJ; Scher HI; Klein RJ; Norton L; Eastham JA; Scardino PT; Robson ME; Offit K
    Clin Cancer Res; 2010 Apr; 16(7):2115-21. PubMed ID: 20215531
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bayesian predictive model to assess BRCA2 mutational status according to clinical history: Early onset, metastatic phenotype or family history of breast/ovary cancer.
    Leon P; Cancel-Tassin G; Bourdon V; Buecher B; Oudard S; Brureau L; Jouffe L; Blanchet P; Stoppa-Lyonnet D; Coulet F; Sobol H; Cussenot O
    Prostate; 2021 May; 81(6):318-325. PubMed ID: 33599307
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer.
    Castro E; Goh C; Olmos D; Saunders E; Leongamornlert D; Tymrakiewicz M; Mahmud N; Dadaev T; Govindasami K; Guy M; Sawyer E; Wilkinson R; Ardern-Jones A; Ellis S; Frost D; Peock S; Evans DG; Tischkowitz M; Cole T; Davidson R; Eccles D; Brewer C; Douglas F; Porteous ME; Donaldson A; Dorkins H; Izatt L; Cook J; Hodgson S; Kennedy MJ; Side LE; Eason J; Murray A; Antoniou AC; Easton DF; Kote-Jarai Z; Eeles R
    J Clin Oncol; 2013 May; 31(14):1748-57. PubMed ID: 23569316
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Frequent germline deleterious mutations in DNA repair genes in familial prostate cancer cases are associated with advanced disease.
    Leongamornlert D; Saunders E; Dadaev T; Tymrakiewicz M; Goh C; Jugurnauth-Little S; Kozarewa I; Fenwick K; Assiotis I; Barrowdale D; Govindasami K; Guy M; Sawyer E; Wilkinson R; ; Antoniou AC; Eeles R; Kote-Jarai Z
    Br J Cancer; 2014 Mar; 110(6):1663-72. PubMed ID: 24556621
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prostate cancer screening in BRCA and Lynch syndrome mutation carriers.
    Castro E; Goh CL; Eeles RA
    Am Soc Clin Oncol Educ Book; 2013; ():. PubMed ID: 23714454
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of BRCA Mutations on Metastatic Relapse and Cause-specific Survival After Radical Treatment for Localised Prostate Cancer.
    Castro E; Goh C; Leongamornlert D; Saunders E; Tymrakiewicz M; Dadaev T; Govindasami K; Guy M; Ellis S; Frost D; Bancroft E; Cole T; Tischkowitz M; Kennedy MJ; Eason J; Brewer C; Evans DG; Davidson R; Eccles D; Porteous ME; Douglas F; Adlard J; Donaldson A; Antoniou AC; Kote-Jarai Z; Easton DF; Olmos D; Eeles R
    Eur Urol; 2015 Aug; 68(2):186-93. PubMed ID: 25454609
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The association between germline BRCA2 variants and sensitivity to platinum-based chemotherapy among men with metastatic prostate cancer.
    Pomerantz MM; Spisák S; Jia L; Cronin AM; Csabai I; Ledet E; Sartor AO; Rainville I; O'Connor EP; Herbert ZT; Szállási Z; Oh WK; Kantoff PW; Garber JE; Schrag D; Kibel AS; Freedman ML
    Cancer; 2017 Sep; 123(18):3532-3539. PubMed ID: 28608931
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Novel prostate cancer susceptibility gene SP6 predisposes patients to aggressive disease.
    Sipeky C; Tammela TLJ; Auvinen A; Schleutker J
    Prostate Cancer Prostatic Dis; 2021 Dec; 24(4):1158-1166. PubMed ID: 34012061
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Germline DNA-repair Gene Mutations and Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Receiving First-line Abiraterone and Enzalutamide.
    Antonarakis ES; Lu C; Luber B; Liang C; Wang H; Chen Y; Silberstein JL; Piana D; Lai Z; Chen Y; Isaacs WB; Luo J
    Eur Urol; 2018 Aug; 74(2):218-225. PubMed ID: 29439820
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rare Germline Pathogenic Mutations of DNA Repair Genes Are Most Strongly Associated with Grade Group 5 Prostate Cancer.
    Wu Y; Yu H; Li S; Wiley K; Zheng SL; LaDuca H; Gielzak M; Na R; Sarver BAJ; Helfand BT; Walsh PC; Lotan TL; Cooney KA; Black MH; Xu J; Isaacs WB
    Eur Urol Oncol; 2020 Apr; 3(2):224-230. PubMed ID: 31948886
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.